Valneva SE (VALN) Return on Capital Employed (2022 - 2026)
Valneva SE's (VALN) quarterly Return on Capital Employed came in at 32.41% in Q1 2026, down 2309.0% year-on-year from 1.47% in Q1 2025, and down 38.09% quarter-over-quarter from 23.47% in Q4 2025.
Valneva SE (VALN) Return on Capital Employed (2022 - 2026) Analysis & Trends
Valneva SE has disclosed Return on Capital Employed across 5 years of filings, most recently posting 32.41% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 32.41%, down 2309.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 32.41% (down 2309.0% YoY), and the FY2025 annual result was 24.45%, down 2808.0% from the prior year.
- Return on Capital Employed came in at 32.41% for Q1 2026 at Valneva SE, down from 23.47% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 37.11% in Q3 2022 to a low of 42.75% in Q4 2023.
- The 5-year median for Return on Capital Employed is 12.89% (2022), against an average of 16.1%.
- Peak annual rise in Return on Capital Employed reached 3835 bps in 2023, while the deepest fall reached 5104 bps in 2023.
- Valneva SE's Return on Capital Employed stood at 32.37% in 2022, then slumped by 32 bps to 42.75% in 2023, then soared by 71 bps to 12.22% in 2024, then slumped by 92 bps to 23.47% in 2025, then plunged by 38 bps to 32.41% in 2026.
- The last three Return on Capital Employed figures came in at 32.41% (Q1 2026), 23.47% (Q4 2025), and 9.35% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -107.40% |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -50.43% |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -32.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.41% |
| Dec 31, 2025 | -23.47% |
| Sep 30, 2025 | -9.35% |
| Jun 30, 2025 | -8.10% |
| Mar 31, 2025 | -9.31% |
| Dec 31, 2024 | -12.22% |
| Sep 30, 2024 | -7.17% |
| Jun 30, 2024 | -8.15% |
| Mar 31, 2024 | -24.91% |
| Dec 31, 2023 | -42.75% |
| Sep 30, 2023 | -13.92% |
| Jun 30, 2023 | -0.35% |
| Mar 31, 2023 | -34.76% |
| Dec 31, 2022 | -32.37% |
| Sep 30, 2022 | 37.11% |
| Jun 30, 2022 | -38.70% |
| Mar 31, 2022 | -12.89% |